---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-029736"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:28:41.930349+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FibroGen Phase 3 ZEPHYRUS-1 trial of pamrevlumab for IPF fails primary endpoint

## Summary
- Phase 3 ZEPHYRUS-1 did not meet primary endpoint: change in FVC at week 48 (p=0.29); placebo-corrected difference 70 ml.
- Secondary endpoint (disease progression or death) also not met (HR=0.78, 95% CI 0.52-1.15).
- ZEPHYRUS-2 Phase 3 IPF trial will be discontinued based on these results.
- Company plans cost reductions to extend cash runway into 2026; roxadustat commercialization continues.
- Upcoming milestones: DMD data 3Q 2023, pancreatic cancer data 1H 2024, new IND filings.

## SEC filing metadata
- accession: 0000950170-23-029736
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023029736/0000950170-23-029736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023029736/fgen-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-029736
- JSON: https://secwatch.observer/filing/0000950170-23-029736.json
- Plain text: https://secwatch.observer/filing/0000950170-23-029736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.